D. thamizh Vani, Malar Sivaraman



To study the efficacy of Roflumilast as an add on therapy and to reduce exacerbations in COPD.


To determine whether Roflumilast improves lung function and decreases exacerbation frequency over a period of 6 months in patients with COPD.

Method: This was a prospective, comparative, randomized, open label study. Patients attending outpatient department of Thoracic medicine diagnosed with COPD with FEV1/FVC < 0.7 were recruited and divided into 2 groups of 50 patients each. Group 1 was administered with standard treatment consisting of Salmeterol and steroid inhalation, while Group 2 patients were administered Roflumilast 500 microgm once daily as add on therapy. Patients were followed every week and enquired for exacerbations and adverse effects. Lung function tests were performed every month using spirometer.

Results: 24 participants were female and the rest 76 were male. There was improvement seen in lung function tests in Roflumilast group compared to control group. All patients in Roflumilast group reported improvement in symptoms such as cough, breathlessness and increase in sputum production and in quality of life compared to control group. Exacerbation of COPD was seen in 3 patients in Roflumilast group compared to 9 patients in control group. The median time to exacerbation was 4.3 months in Roflumilast group compared to 2.8 months in control group.

Conclusion: Data suggest that roflumilast reduces moderate to severe exacerbations with the benefit most well established in patients with severe disease.


Roflumilast, Exacerbation, spirometer

Full Text:



Vestbo, Jorgen (2013). "Definition and Overview". Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Global Initiative for Chronic Obstructive Lung Disease. pp. 1–7.

BD 2015 Disease and Injury Incidence and Prevalence, Collaborators. (8 October 2016). "Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015."Lancet. 388 (10053): 1545–1602. doi:10.1016/S0140-6736(16)31678-6.

Chronic obstructive pulmonary disease (COPD) Fact sheet N°315". WHO. January 2015. Retrieved 4 March 2016.

Rennard, Stephen (2013). Clinical management of chronic obstructive pulmonary disease (2nd ed.). Informa Healthcare. p. 23.

Goldman, Lee (2012). Goldman's Cecil medicine (24th ed.). Elsevier/Saunders. p. 537. ISBN 978-1-4377-1604-7.

Foreman MG, Campos M, Celedón JC (July 2012). "Genes and chronic obstructive pulmonary disease". Med. Clin. North Am. 96 (4): 699–711 doi:10.1016/j.mcna.2012.02.006

Vestbo, Jørgen (2013). "Management of Exacerbations" (PDF). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Global Initiative for Chronic Obstructive Lung Disease. pp. 39–45.

Dhar, Raja (2011). Textbook of pulmonary and critical care medicine. New Delhi: Jaypee Brothers Medical Publishers. p. 1056. ISBN 978-93-5025-073-0.

Palange, Paolo (2013). ERS Handbook of Respiratory Medicine. European Respiratory Society. p. 194. ISBN 978-1-84984-041-5.

Lötvall, Jan (2011). Advances in combination therapy for asthma and COPD. Wiley. p. 251. ISBN 978-1-119-97846-6.

Barnes, Peter. Asthma and COPD: basic mechanisms and clinical management(2nd ed.). Academic. p. 837. ISBN 978-0-12-374001-4.

Young, Vincent B. Blueprints medicine (5th ed.). Wolters Kluwer Health/Lippincott Williams & Wilkins. p. 69. ISBN 978-0-7817-8870-0

Qaseem, Amir; Wilt, TJ; Weinberger, SE; Hanania, NA; Criner, G; et al American College Of Physicians; American College of Chest Physicians; American Thoracic Society; European Respiratory Society (2011). "Diagnosis and Management of Stable Chronic Obstructive Pulmonary Disease: A Clinical Practice Guideline Update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society". Annals of Internal Medicine. 155. doi:10.7326/0003-4819-155-3-201108020-00008.

National Institute for Health and Clinical Excellence. Clinical guideline 101: Chronic Obstructive Pulmonary Disease. London, June 2012.

Mammen MJ, Sethi S (2012). "Macrolide therapy for the prevention of acute exacerbations in chronic obstructive pulmonary disease". Pol. Arch. Med. Wewn. 122 (1–2): 54–9. PMID 22353707.

Herath, SC; Poole, P (Nov 28, 2013). "Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD)." Cochrane Database Syst Rev. 11: CD009764. doi:10.1002/14651858.CD009764.pub2.

Simoens, S; Laekeman, G; Decramer, M (May 2013). "Preventing COPD exacerbations with macrolides: a review and budget impact analysis". Respiratory medicine. 107 (5): 637–48. PMID 23352223. doi:10.1016/j.rmed.2012.12.019.

Barr RG, Rowe BH, Camargo CA. Barr, R Graham, ed. "Methylxanthines for exacerbations of chronic obstructive pulmonary disease". doi:10.1002/14651858.CD002168.

Poole, P; Chong, J; Cates, CJ (29 July 2015). "Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease."Cochrane Database Syst Rev. 7 doi : 10.1002/ 14651858. CD001287 .pub5.

COPD Working, Group (2012). "Long-term oxygen therapy for patients with chronic obstructive pulmonary disease (COPD): an evidence-based analysis". Ontario health technology assessment series.

Bradley JM, O'Neill B, Bradley, Judy M, et al. "Short-term ambulatory oxygen for chronic obstructive pulmonary disease". doi:10.1002/14651858.CD004356.pub3.

Ekström, Magnus; Ahmadi, Zainab; Bornefalk-Hermansson, Anna; Abernethy, Amy; Currow, David (2016-11-25). "Oxygen for breathlessness in patients with chronic obstructive pulmonary disease who do not qualify for home oxygen therapy". doi:10.1002/14651858.CD006429.pub3.

Chapman, Stephen. Oxford handbook of respiratory medicine (2nd ed.). Oxford University Press. p. 707. ISBN 978-0-19-954516-2.

Blackler, Laura. Managing chronic obstructive pulmonary disease. p. 49. ISBN 978-0-470-51798-7.

Jindal, Surinder K (2013). Chronic Obstructive Pulmonary Disease. Jaypee Brothers Medical. p. 139. ISBN 978-93-5090-353-7.

Reduction of exacerbations by the PDE4 inhibitor roflumilast - the importance of defining different subsets of patients with COPD, Stephen I Rennard DOI: 10.1186/1465-9921-12-18

The glucose-lowering effects of the PDE4 inhibitors roflumilast and roflumilast-N-oxide in db/db mice, Vollert s et al., 2012 Oct;55(10):2779-2788. doi: 10.1007/s00125-012-2632-z.

Roflumilast: a review of its use in the treatment of COPD Int J Chron Obstruct Pulmon Dis. 2016; 11: 81–90

Roflumilast : risk of suicidal behaviour

From:Medicines and Healthcare products Regulatory Agency 29 January 2013

Risk factors for chronic obstructive pulmonary disease: Results of the FARIECE study Aguirre.K.A.Guzmán-Guillen.M.E.Álvarez-Serrano J.R.Vintimilla-Maldonado.


  • There are currently no refbacks.